References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailComparison of the effects of nimesulide and nimesulide-L-lysine on PGE2 production by COX-1 and COX-2 and on chondrocyte metabolism in vitro
De Leval, X.; Henrotin, Y.; Labasse, A. et al

in Pharmacy and Pharmacology Communications (2000), 6

Detailed reference viewed: 2 (2 ULg)
Peer Reviewed
See detailComparative effects of nimesulide, nimesulide L-lysine and nimesulide L-lysine L-arginine on human articular chondrocytes in vitro
De Leval, X.; Dogné, Jean-Michel ULg; Delarge, J. et al

in Mediators of Inflammation (2000), 9

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailIn vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR).
Mouithys-Mickalad, Ange ULg; Zheng, S. X.; Deby-Dupont, G. P. et al

in Free Radical Research (2000), 33(5), 607-21

OBJECTIVES: To determine the antioxidant activities of nonsteroidal anti-inflammatory drugs (NSAIDS), we examined by chemiluminescence (CL) and electron spin resonance (ESR) their scavenging properties ... [more ▼]

OBJECTIVES: To determine the antioxidant activities of nonsteroidal anti-inflammatory drugs (NSAIDS), we examined by chemiluminescence (CL) and electron spin resonance (ESR) their scavenging properties towards lipid peroxides, hypochlorous acid and peroxynitrite. METHODS: The antioxidant properties of nimesulide (NIM), 4-hydroxynimesulide (4-HONIM), aceclofenac (ACLO), 4-hydroxyaceclofenac (4-HOA-CLO), diclofenac (DICLO) and indomethacin (INDO) were tested on four different reactive oxygen species (ROS) generating systems: (I) phorbol-myristate acetate (PMA)-activated neutrophils, (II) Fe2+/ascorbate-induced lipid peroxidation, (III) HOCl-induced light emission, (IV) the kinetics of ONOO- decomposition followed by spectrophotometry. ROS production was monitored by luminol-enhanced CL or by ESR using two different spin traps. RESULTS: At 10 microM, ACLO, NIM, 4-HONIM, 4-HOA-CLO, and DICLO decreased luminol-enhanced CL generated by PMA-activated neutrophils. Inversely, INDO increased the luminol enhanced CL. Interestingly, hydroxylated metabolites were more potent antioxidants than the parent drugs. Furthermore, all drugs tested, excepted ACLO, lowered lipid peroxidation induced by Fe2+/ascorbate system. ACLO and DICLO, even at the highest concentration tested (100 microM), did not significantly lower HOCl induced CL, whereas the other drugs were potent scavengers. Finally, all the NSAIDS accelerated decomposition of ONOO-, suggesting a potential capacity of the molecules to scavenge peroxynitrite. CONCLUSION: The NSAIDs possess variable degrees of antioxidant activities, linked to their ability to react with HOCl, lipid peroxides or ONOO-. These antioxidant activities could offer interesting targeted side-effects in the treatment of joint inflammatory diseases. [less ▲]

Detailed reference viewed: 13 (4 ULg)
Peer Reviewed
See detailThe simple calculated osteoporosis risk estimation (SCORE) does not allow identification of Belgian women with a high risk of osteoporosis
Ben Sedrine, Wafa ULg; Devogelaer, Jean-Pierre; Kaufman, Jean-Marc et al

in Annals of the Rheumatic Diseases (2000), 59(Suppl.1), 80

Detailed reference viewed: 20 (4 ULg)
Peer Reviewed
See detailInterest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry
Ben Sedrine, Wafa ULg; Devogelaer, Jean-Pierre; Kaufman, Jean-Marc et al

in Annals of the Rheumatic Diseases (2000), 59(Suppl.1), 80-81

Detailed reference viewed: 20 (11 ULg)
See detailEvaluation isocinétique des muscles du genou au cours de la gonarthrose
Croisier, Jean-Louis ULg; Henrotin, Yves ULg; Dumont, Régine ULg et al

in Isocinétisme et personnes âgées (2000)

Detailed reference viewed: 43 (1 ULg)
See detailBisphosphonates
Reginster, Jean-Yves ULg; Paul, I.; Fraikin, G. et al

in The management of the menopause : the Millenium Review (2000)

Detailed reference viewed: 7 (3 ULg)
See detailSkeletal effect of selective oestrogen receptor modulators (SERMs)
Reginster, Jean-Yves ULg; Taquet, A.-N.; Bruyère, Olivier ULg

in SERMs, a novel option to maintain health in the menopause (2000)

Detailed reference viewed: 5 (2 ULg)
Peer Reviewed
See detailEvidence of nutriceutical effectiveness in the treatment of osteoarthritis
Reginster, Jean-Yves ULg; Gillot, Vincent; Bruyère, Olivier ULg et al

in Current Rheumatology Reports (2000), 2(6), 472-477

Detailed reference viewed: 5 (4 ULg)
Peer Reviewed
See detailProfile of nimesulide and nimesulide-L-lysine-β-cyclodextrin on chondrocyte metabolism
De Leval, X.; Dogne, J. M.; Masereel, B. et al

Poster (1999, November 20)

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailAssociation of Tibolone and Fluoride Displays a Pronounced Effect on Bone Mineral Density in Postmenopausal Osteoporotic Women
Reginster, Jean-Yves ULg; Agnusdei, D.; Gennari, C. et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (1999), 13(5), 361-8

A double-blind, placebo-controlled, randomized, prospective two-center study was carried out to assess the effects of tibolone + fluoride versus placebo + fluoride therapy on trabecular and cortical bone ... [more ▼]

A double-blind, placebo-controlled, randomized, prospective two-center study was carried out to assess the effects of tibolone + fluoride versus placebo + fluoride therapy on trabecular and cortical bone in postmenopausal osteoporotic women. Ninety-four subjects (mean age 61.1 years, postmenopausal 13.5 years on average) with low bone mineral density (BMD) at baseline were randomized to 2.5 mg of tibolone (Org OD 14, Livial) plus 26.4 mg of fluoride (Fluocalcic) or placebo plus 26.4 mg of fluoride daily over 2 years; 55 (58.5%) subjects completed the study, the main reason for discontinuation being untoward gastrointestinal effects. BMD at the lumbar spine was measured by both dual photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DXA), and at the hip by DXA at 6-month intervals. Baseline values (DXA, g/cm2) for tibolone + fluoride and placebo + fluoride groups were 0.733 and 0.744 for the lumbar spine, and 0.761 and 0.788 for the hip. Change from baseline and percentage change from baseline were calculated for the intent-to-treat and completers groups. An analysis of variance (ANOVA) model or Wilcoxon test was used for statistical evaluation. There was a mean increase in BMD at the lumbar spine measured by DPA of 25.3% and 12.3% in tibolone + fluoride and placebo + fluoride groups, respectively (p = 0.01); with DXA, respective changes were 32.6% and 14.0% (p = 0.013). Data on BMD at the hip showed mean increases of 7.9% and 2.6% for the tibolone + fluoride and placebo + fluoride groups, respectively. We conclude that combined tibolone + fluoride treatment induces a highly significant increase in BMD at the lumbar spine without simultaneous loss of the cortical bone allowing for a meaningful reduction of the fluoride dose when given in combination with tibolone. [less ▲]

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailAlphacalcidol in Prevention of Glucocorticoid-Induced Osteoporosis
Reginster, Jean-Yves ULg; de Froidmont, C.; Lecart, M. P. et al

in Calcified Tissue International (1999), 65(4), 328-31

One of the major drawbacks of glucocorticoids long-term therapy is the occurrence of a severe osteoporosis characterized by fractures occurring at different sites, mainly at the level of trabecular bone ... [more ▼]

One of the major drawbacks of glucocorticoids long-term therapy is the occurrence of a severe osteoporosis characterized by fractures occurring at different sites, mainly at the level of trabecular bone. One of the major determinants of glucocorticoid-induced osteoporosis is a decrease in the intestinal absorption of calcium (Ca) leading to a secondary hyperparathyroidism. D-hormones have been shown to significantly improve Ca absorption in the gut and subsequently to decrease parathyroid hormone circulating levels, hence normalizing bone turnover. In a recent study evaluating 145 patients suffering from diseases requiring long-term treatment with high doses of corticosteroids, we have demonstrated a significant benefit of alphacalcidol (1 microg/day) over placebo in terms of changes in bone mineral density of the lumbar spine. These results are in accordance with studies showing better prevention of bone loss and vertebral fractures in cardiac transplant patients treated with alphacalcidol than those treated with etidronate. There is now a convergent body of evidence to suggest that alphacalcidol is a reasonable, safe, and effective option for the prevention of glucocorticoid-induced osteoporosis, provided that serum Ca is monitored on a regular basis. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Peer Reviewed
See detailComparative effects of nimesulide, nimesulide L-lysine and nimesulide L-lysine L-arginine on human articular chondrocytes in vitro
De Leval, X.; Dogne, J. M.; Delarge, J. et al

Poster (1999, September 17)

Detailed reference viewed: 13 (6 ULg)
Peer Reviewed
See detailSynthesis and evaluation of non-carboxylic pyridinic derivatives as cyclooxygenase inhibitors
Dogne, J. M.; De Leval, X.; Delarge, J. et al

Poster (1999, September 17)

Detailed reference viewed: 12 (7 ULg)
Peer Reviewed
See detailEvaluation de la sélectivité COX-1 vs COX-2 de drogues à potentialités anti-inflammatoires
De Leval, X.; Dogne, J. M.; Neven, Ph. et al

Poster (1999, May)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailAnabolic Events in Osteoarthritis
Henrotin, Yves ULg; Reginster, Jean-Yves ULg

in Osteoarthritis and Cartilage (1999), 7(3), 310-2

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailIn-Vitro Differences among Nonsteroidal Antiinflammatory Drugs in Their Activities Related to Osteoarthritis Pathophysiology
Henroitin, Y.; Reginster, Jean-Yves ULg

in Osteoarthritis and Cartilage (1999), 7(3), 355-7

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose d'involution chez la femme
Reginster, Jean-Yves ULg; Devogelaer, J. P.; Kaufman, J. M. et al

in Revue Médicale de Liège (1999), 54(4), 335-40

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches ... [more ▼]

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches were developed for the prevention and treatment of osteoporosis. Besides regular physical exercise and calcium rich diet, calcium supplementation can be suggested to both genders, after seventy years as well as systematic vitamin D supplementation in order to cope with the frequent lack observed in our country. Hormone replacement therapy is the first choice in prevention of postmenopausal osteoporosis. Based on a careful evaluation of the needs of a postmenopausal woman as well as on the risk/benefit ratio derived from her individual risk factors, selective estrogen receptor modulators (raloxifene) or second generation bisphosphonates (alendronate) can be considered as alternative to estrogens. Due to its prohibitive cost, nasal calcitonin should be only considered for very specific cases. In osteoporosis confirmed by bone densitometry or by occurrence of fractures, bisphosphonate (alendronate) reduces subsequent fracture rate. Fluoride salts can, in some cases, improve spinal symptomatic osteoporosis. The use of etidronate, a molecule from the past, should be avoided as much as possible and, at any rate, strictly restricted to its legal indication including women with several vertebral crush fractures and severely decreased bone mineral density. [less ▲]

Detailed reference viewed: 46 (3 ULg)